GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties
Authors
Keywords
-
Journal
Biology-Basel
Volume 10, Issue 7, Pages 610
Publisher
MDPI AG
Online
2021-07-01
DOI
10.3390/biology10070610
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GSK3B induces autophagy by phosphorylating ULK1
- (2021) Hye Young Ryu et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer
- (2021) Ning Zhang et al. Cell Death & Disease
- LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer
- (2021) Lena Seifert et al. Cancers
- GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals
- (2021) Stephen L. Abrams et al. Cells
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
- (2021) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity
- (2020) Christopher E. Rudd et al. Cell Reports
- Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer
- (2020) Li Ding et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors.
- (2020) Benedito A. Carneiro et al. JOURNAL OF CLINICAL ONCOLOGY
- HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
- (2020) Holly Brunton et al. Cell Reports
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
- (2020) Przemysław Duda et al. Cells
- LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
- (2020) D.J. Renouf et al. ANNALS OF ONCOLOGY
- The Immune Microenvironment in Pancreatic Cancer
- (2020) Magdalena Huber et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor
- (2020) Sean D. Allen et al. BIOMATERIALS
- Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
- (2019) Xiaosheng Wu et al. BLOOD
- Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses
- (2019) Ilyas Sahin et al. CANCER BIOLOGY & THERAPY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Chemoresistance in Pancreatic Cancer
- (2019) Zeng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer
- (2019) Raffaela Santoro et al. MOLECULAR CANCER THERAPEUTICS
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Metabolism in Pancreatic Cancer
- (2019) Liang Yan et al. Cancers
- Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
- (2019) Tsutomu Anraku et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
- (2019) Ann Jeffers et al. Scientific Reports
- 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
- (2019) Hiroo Kuroki et al. Scientific Reports
- 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma
- (2018) Andrey V. Ugolkov et al. ANTI-CANCER DRUGS
- Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells
- (2018) Sadhak Sengupta et al. CANCER LETTERS
- Modulation of CD8+ memory stem T cell activity and glycogen synthase kinase 3β inhibition enhances anti-tumoral immunity in gastric cancer
- (2018) Jin-yu Zhang et al. OncoImmunology
- Aberrant expression of glycogen synthase kinase‑3β in human breast and head and neck cancer
- (2018) Andrey Ugolkov et al. Oncology Letters
- An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice
- (2018) Mouad Edderkaoui et al. GASTROENTEROLOGY
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
- (2017) Aleksandra Adamska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models
- (2017) Andrey Ugolkov et al. Translational Oncology
- Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy
- (2017) Alison Taylor et al. Frontiers in Immunology
- Over-expression of microRNA-940 promotes cell proliferation by targeting GSK3β and sFRP1 in human pancreatic carcinoma
- (2016) Hong-wei Yang et al. BIOMEDICINE & PHARMACOTHERAPY
- GSK-3 inhibition overcomes chemoresistance in human breast cancer
- (2016) Andrey Ugolkov et al. CANCER LETTERS
- Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses
- (2016) Alison Taylor et al. IMMUNITY
- GSK-3 Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
- (2016) S. Baumgart et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells
- (2016) James A. McCubrey et al. Oncotarget
- GSK3β mediates pancreatic cancer cell invasion in vitro via the CXCR4/MMP-2 Pathway
- (2015) Xu Ying et al. Cancer Cell International
- Glycogen synthase kinase-3 (Gsk-3) plays a fundamental role in maintaining DNA methylation at imprinted loci in mouse embryonic stem cells
- (2015) Gavin D. Meredith et al. MOLECULAR BIOLOGY OF THE CELL
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
- (2015) Eleonore Beurel et al. PHARMACOLOGY & THERAPEUTICS
- MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway
- (2015) Wei Zhou et al. Oncotarget
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- Regulation of MDA-MB-231 cell proliferation by GSK-3β involves epigenetic modifications under high glucose conditions
- (2014) Chanchal Gupta et al. EXPERIMENTAL CELL RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Lithium Inhibits Tumorigenic Potential of PDA Cells through Targeting Hedgehog-GLI Signaling Pathway
- (2014) Zhonglu Peng et al. PLoS One
- Glycogen synthase kinase-3 beta regulates Snail and β-catenin expression during Fas-induced epithelial–mesenchymal transition in gastrointestinal cancer
- (2013) Haoxuan Zheng et al. EUROPEAN JOURNAL OF CANCER
- Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer
- (2013) K. Pal et al. MOLECULAR CANCER THERAPEUTICS
- Aberrant Glycogen Synthase Kinase 3β Is Involved in Pancreatic Cancer Cell Invasion and Resistance to Therapy
- (2013) Ayako Kitano et al. PLoS One
- Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth
- (2011) Tyvette S. Hilliard et al. ANTI-CANCER DRUGS
- ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer
- (2011) Wei Zhou et al. CANCER LETTERS
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine
- (2011) Takeo Shimasaki et al. JOURNAL OF GASTROENTEROLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer
- (2011) J-S Zhang et al. ONCOGENE
- GSK-3: Functional Insights from Cell Biology and Animal Models
- (2011) Oksana Kaidanovich-Beilin et al. Frontiers in Molecular Neuroscience
- Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy
- (2009) Shadi Mamaghani et al. BMC CANCER
- Deregulated GSK3 Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and Telomerase
- (2009) W. Mai et al. CLINICAL CANCER RESEARCH
- GSK3: a multifaceted kinase in Wnt signaling
- (2009) Dianqing Wu et al. TRENDS IN BIOCHEMICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More